Analysts Set Expectations for AC Immune FY2024 Earnings

AC Immune SA (NASDAQ:ACIU) – Research analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of AC Immune in a report issued on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of ($0.60) for the year, up from their prior forecast of ($0.81). The consensus estimate for AC Immune’s current full-year earnings is ($0.89) per share. Leerink Partnrs also issued estimates for AC Immune’s Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.87) EPS and FY2028 earnings at $0.00 EPS.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of $0.42 by ($0.67). The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $91.60 million.

Several other brokerages have also recently commented on ACIU. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research report on Wednesday. StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

AC Immune Trading Down 2.1 %

ACIU opened at $3.20 on Friday. The stock’s 50-day moving average price is $3.27 and its 200 day moving average price is $3.45. AC Immune has a 12-month low of $2.25 and a 12-month high of $5.14. The firm has a market cap of $316.61 million, a price-to-earnings ratio of -4.44 and a beta of 1.28.

Institutional Trading of AC Immune

A number of institutional investors have recently bought and sold shares of ACIU. BNP Paribas Financial Markets boosted its holdings in shares of AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after acquiring an additional 8,423 shares during the period. Lazard Asset Management LLC purchased a new position in AC Immune during the 1st quarter worth $30,000. Redmile Group LLC increased its stake in AC Immune by 0.4% in the first quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock valued at $5,941,000 after purchasing an additional 7,031 shares during the period. Silverberg Bernstein Capital Management LLC purchased a new stake in shares of AC Immune in the second quarter valued at about $40,000. Finally, Assenagon Asset Management S.A. boosted its stake in shares of AC Immune by 294.7% during the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after buying an additional 328,312 shares during the period. 51.36% of the stock is owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.